Tablets for oral use – Use in canines
Inhibition of the renin – angiotensin axis
Enalapril is converted by the liver into the active compound enaprilato. The enaprilato prevents formation of angiostensina II competing with angiotensin I. This decreases the concentrations of angiotensin II, the aldosterone secretion that decreases and increases plasma renin activity.
The effects of enalaprilat in patients with congestive heart failure are decreased total peripheral resistance, pulmonary vascular resistance, mean arterial pressure and right atrial pressure and capillary lace pulmonary unchanged or decreased heart rate and increased heart rate and minute volume, systolic unloading and tolerance to effort.
Kidney blood flow may increase with little change in hepatic blood flow.
It plays a dual role reducing vasoconstriction and indirectly reduces water retention and sodium aldosterone levels decrease and ADH. It causes vasodilatation by increased levels of circulating bradquinina and decreases degradation and E-2 increases prostaglandin levels by blocking the enzymes.
FORMULA | Each tablet contains:
Enalapril Maleate …………………… 10 mg
Excipients ……………………. 250 mg
Use in canines.
It is a mixed arteriovenous vasodilator in the treatment of heart failure and hypertension. Helps in glomerular disease and protein losing neuropathies. Indicated in the treatment of congestive heart failure caused by valvular diseases of any etiology. Its use reduces mortality and increases the quality of life in dogs with moderate to severe cases of congestive heart failure using either monotherapy alone or associating digoxin and / or furosemide. Improves hemodynamics in patients with congestive heart failure, decreases vascular resistance and increases cardiac output.
With its use is achieved:
-Reduce Pulmonary capillary blood pressure with improved clinical symptoms of pulmonary congestion.
-Reduce Pulmonary arterial blood pressure so that the blood pressure of the right atrium is decreased, improving the clinical symptoms of abdominal congestion.
-Mild decrease in heart rate.
-Decreased systemic peripheral blood pressure.
-Decreases in media arterial pressure, decreases peripheral vascular resistance and lowers the strength needed to beat the heart in systole (afterload), thus increasing cardiac output and the volume of blood pumped in each systole.
-Increase exercise tolerance, thereby decreasing the category of congestive heart failure NYHA (New York Heart Association)
-When there is pulmonary edema it reduces it and may even eliminate it.
-Delays or stops the process of compensatory hypertrophy of the ventricular myocardium
-Eliminates selective glomerular arteriolar vasoconstriction of afferent, decreasing the pressure filter that may sometimes trigger a reversible kidney failure, with elevated levels of plasma urea and creatinine.
-Removes the effect of tubular aldosterone that was producing excessive sodium retention.
ADMINISTRATION AND DOSAGE
The recommended dose in dogs is 1 tablet of Cardiovet every 20 kg of weight (0.5 mg / kg) every 12 or 24 hours depending on the patient’s condition and the observed response.
It starts with a daily dose and if the response is inadequate 1 tablet of Cardiovet c / 20 kg (0.5 mg / kg body weight) administered every 12 hours.
Adverse effects are gastrointestinal disturbances (anorexia, vomiting, diarrhea). Serial monitoring of renal function should be performed in patients with associated neuropathies. Wide safety margin. The lethal dose in dogs is 200 mg / Kg
PRESENTATIONS: Box containing 30 tablets.
Keep between 5 ° and 35 ° C